National Institute of Health and Medical Research

Assistance Publique-Hopitaux De Paris

Université Paris Descartes

Institut Gustave Roussy

Centre Henri Becquerel

Université Paris—sud

Université Pierre Et Marie Curie (Paris 6)

Université Pierre Et Marie Curie

Centre National De La Recherche Scientifique

Assistance Publique - Hopitaux De Paris (Aphp)

Université Paris-Sud 11

Apogenix Ag

Fondation Imagine

Universite Paris Cité

Michaela Fontenay

William Vainchenker

Olivier Bernard

Christian Bastard

Franck Viguie

Francois Delhommeau

Olivier Hermine

Claudia Kunz

Harald Fricke

Flavia Guillem

Jean-Benoit Arlet

Genevève Courtois

François Delhommeau

The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO: 2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour.

TET2 as a diagnostic and pronostic marker in hematopoietic neoplasms

TET2 as a diagnostic and prognostic marker in hematopoietic neoplasms

The present invention provides methods and pharmaceutical compositions designed to intervene in this defective process and to promote or restore erythrocyte maturation in individuals suffering from a myelodysplastic syndrome. The methods involve maintaining the activity of GATA-1 by preventing sequestration of Hsp70 in the cytoplasm. Accordingly, it is an object of this invention to provide methods of restoring or increasing erythrocyte maturation in a subject suffering from a myelodysplastic syndrome by preventing proteolytic inactivation of GATA-1. In some embodiments, preventing is achieved by administering to the subject a compound that inhibits the XPO1 nuclear transporter.

Methods and pharmaceutical compositions for the treatment of myelodysplastic syndromes

The present invention relates to inhibitors of the CD95 signaling pathway for the use in the treatment of Myelodysplastic Syndrom (MDS) wherein the MDS is selected from the IPSS low risk MDS subgroup and/or the IPSS intermediate-1 (int-1) risk MDS subgroup as well as a method for the diagnosis of MDS.

Inhibitors of the CD95 signaling pathway for treatment of MDS

The present invention concerns an in vitro method for diagnosing a myeloid tumor or a lymphoid tumor in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO:2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumor or a lymphoid tumor.

TET2 as a new diagnostic and pronostic marker in hematopoietic neoplasms

Growing community of inventors

Paris, France

Michaela Fontenay